Community curated by people like you

Michael Sena stories

Nov 2, 2026

Fresenius signs biosimilars development agreement with WuXi Biologics

German healthcare company Fresenius has entered a partnership with China's WuXi Biologics to develop a pipeline of biosimilar drugs, expanding its presence in the biologics market.

Nov 2, 2026·3 sources

00

Top claims

▪Fresenius SE agreed to a pay-as-you-go structure for its biosimilars development agreement with WuXi Biologics, allowing Fresenius SE flexibility to halt individual biosimilar programs if necessary
▪WuXi Biologics was spun off from WuXi AppTec in 2017 as a contract developer and manufacturer for brand-name drugmakers
▪The biosimilars development deal with WuXi Biologics could expand the total molecule portfolio at Fresenius SE from 29 to as many as 66 by the next decade

Topics

Pharmaceutical Industry Corporate strategy Biologic therapies U.S. Department of Defense Generic drugs & biosimilars Drug development Biotechnology

Related entities